Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KAT6 inhibitor MEN2312

An orally bioavailable inhibitor of MYST histone acetyltransferase (HAT) KAT6, with potential antineoplastic activity. Upon oral administration, KAT6 inhibitor MEN2312 targets and binds to KAT6, and inhibits the acetylation of histones and other nonhistone substrates. This may disrupt gene expression and inhibit the proliferation of tumors that overexpress KAT6. KAT6A (MOZ; MYST3) and KAT6B (MORF; MOZ2; MYST4), commonly amplified genes in solid tumors, play key roles in cell cycle regulation and in tumorigenesis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	KAT6A/B inhibitor MEN2312 KAT6A/KAT6B inhibitor MEN2312
Code name:	MEN 2312 MEN-2312 MEN2312

KAT6 inhibitor MEN2312

Search NCI's Drug Dictionary